This site is intended for healthcare professionals
Managing Osteoarthritis-associated Pain
Declaration of sponsorship Pfizer and Lilly

Expert opinion

Declaration of sponsorship Pfizer and Lilly
Read time: 55 mins
Last updated:4th Feb 2022
Published:9th Jul 2020
  • Watch our virtual roundtable discussion to learn from medical experts
  • Explore the unmet needs for pain management in patients with OA
  • Investigate the patient-centred approach to OA pain management

Chair Professor David Walsh introduces the roundtable discussion, which aims to help develop physician beliefs and behaviours in line with current guidelines in order to build on the patient-centred approach to osteoarthritis (OA) pain management.

Professor Walsh begins by introducing himself and his fellow faculty.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Professor Walsh poses questions to the faculty around personalised pain management for patients with OA,

along with pain assessment and the risk/benefit considerations of treatment.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Professor Walsh invites the faculty’s opinion on the current guidelines, the importance of exercise, 

whether to use drug combinations and common misconceptions in treating OA pain.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Given the previously discussed limitation of current treatments, Professor Walsh 

questions the faculty on emerging therapies for OA pain.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Professor Walsh closes the roundtable and thanks his fellow faculty. People with OA pain have suffered enough and while there are new and emerging treatments that hold much potential,

more people can also gain much more benefit from existing treatments if we use a personalised and holistic approach.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Put your knowledge of osteoarthritis-related pain to the test with this interactive quiz based on our recent virtual roundtable meeting, including:

  • considerations when treating osteoarthritis
  • the effectiveness of combination therapy
  • the response in terms of pain and function to regular exercise
  • tolerability of NSAIDs
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. Birbara C, Dabezies EJ, Burr AM, Fountaine RJ, Smith MD, Brown MT, et al. Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis. J Pain Res. 2018;11:151–164.
  2. Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzler TJ et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: A phase IIb/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 2019;71(11):1824–1834.

2. Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzler TJ et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: A phase IIb/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 2019;71(11):1824–1834.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: